Key result
The risk of death while waiting for intervention for severe aortic stenosis in routine clinical practice ranges from 2.7% to 14%, which is higher than the 0% to 1.4% seen in clinical trials.
Why the study?
Mortality whilst waiting for intervention in symptomatic severe aortic stenosis is higher than procedural mortality and lacks guideline benchmarks or performance metrics.
Answers are grounded in this paper and cite their sources.
Waiting mortality up to 14% in severe AS signals triage urgency; leaves open optimal strategies to shorten delays.
An increasing number of patients with severe aortic stenosis (AS) are undergoing intervention as the population ages and access to transcatheter therapies increases.1 Identification, assessment, decision-making, and treatment of AS mandates a waiting time for intervention. Symptomatic patients with AS are at risk of sudden death and heart failure.2 The risk of death whilst waiting for intervention in routine clinical practice ranges from 2.7% and 14% (Table 1 and Supplementary material online, References 1–6) and is higher than in patients enrolled in clinical trials (0–1.4%) (Table 2 and Supplementary material online, References 7–14). In addition, patients classified as high risk for valve surgery have a higher waiting list mortality prior to either surgical or transcatheter aortic valve intervention (0.9%) than those classified as low risk (0.2%) (Table 2). Risk factors for waiting list mortality include time on the waiting list, heart failure, impaired left ventricular function, worsening functional class, and other comorbidities.3 Studies examining mortality whilst undergoing assessment for aortic valve intervention AVR, aortic valve replacement; TAVR, transcatheter aortic valve replacement. Studies examining mortality whilst undergoing assessment for aortic valve intervention AVR, aortic valve replacement; TAVR, transcatheter aortic valve replacement. Randomized clinical trials of severe aortic stenosis NA, not applicable; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement. Randomized clinical trials of severe aortic stenosis NA, not applicable; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement. The clinical pathway for AS assessment incorporates several stages including clinical review, diagnostics (echocardiography and computed tomography and/or coronary angiography), heart team meeting and waiting time from procedure listing to intervention. At present, there are no guidelines or benchmarks for the waiting time from diagnosis to intervention in AS. Ideally, intervention should occur as soon as possible to reduce the risk of sudden death. Current metrics proposed for heart valve centres focus on outcomes post-intervention, e.g. 30 days mortality.4 We believe performance measures should include the whole pathway, incorporating the waiting list period when mortality often exceeds procedural mortality, in order to reduce delays from diagnosis through to treatment. In conclusion, waiting list mortality for patients with severe AS has received inadequate attention from clinicians. We propose the development of whole pathway performance metrics as means to reduce wait times and improve overall outcomes. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Bhattacharyya et al. (2019) conducted an editorial in Severe aortic stenosis. Waiting time for aortic valve intervention was evaluated on Waiting list mortality. The risk of death while waiting for intervention for severe aortic stenosis in routine clinical practice ranges from 2.7% to 14%, which is higher than the 0% to 1.4% seen in clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: